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Yue-Hui Yang*, Jun Yang and Qing-Hua JiangAbstract
Background: To investigate the anti-hyperlipidemic effect of gynosaponins (GPs) in hyperlipidemic rats induced by
high lipid diet.
Methods: Animal model of hyperlipidemia was established by high-fat and high-cholesterol diet. Rats were
randomly divided into 6 groups, except the normal and model groups, rats in GPs groups were daily administered
intragastrically with GPs (50, 100, and 200 mg/kg), and rats in simvastatin group were daily administered
intragastrically with simvastatin (10 mg/kg). It was measured that the contents of glutathione peroxidase (GSH-Px),
superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA), total cholesterol (TC), triglyceride (TG),
high-density lipoprotein-cholesterol (HDL-C) and low-density lipoprotein-cholesterol (LDL-C) in the serum, TG and
TC in the liver during this experiment, respectively. The left lobe of liver was observed by histopathological staining,
and the immunohistochemical staining was used to observe the effects on the effect of GPs on liver functions.
Results: Compared with the model group, GPs groups could remarkably decrease the content of lipids, GSH-Px,
SOD, CAT and MDA in the serum and TC and TG in the liver of the hyperlipidemic rats. The pathomorphological
results of hepatic tissue showed that fatty degeneration and inflammatory reaction of GPs groups were lightened
compared with the model group.
Conclusions: The results show that GPs has good effects on the treatment of hyperlipidemia induced by high lipid
diet in rats. The possible anti-hyperlipidemia mechanism maybe those GPs can regulate the disorder of lipid
metabolism as well as ameliorate hepatic function.
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Hyperlipidemia has been thought to be a modifiable risk
of cardiovascular disease, a most common cause of mor-
tality worldwide, accounting for almost 17 million deaths
annually [1]. Generally, bile acid sequestrants, statins,
fibrates and nicotinic acids are efficacious antihyperlipi-
daemic drugs currently available, but adverse reactions
and quality of life morbidity indicates the need to find
safe and highly effective regimens for dyslipidemia.
To date, herbal medicines are widely used to treat
variety of disease. Gypenosides (GPs) are triterpenoid
saponins contained in an extract from Gynostemma pen-
taphyllum and are reported to be effective in treating in-
flammatory [2], cancer and cardiovascular disease [3]. It’s* Correspondence: yangyuehui20130913@126.com
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stated.reported that GPs contains 84 saponins, and 4 of them
(Gyp-3, 4, 8, 12) are synonym of ginsenoside (Gin-Rb1,
Rb3, Rd, F2), including gynosaponins that have been iso-
lated and identified in Asia and suggested to have a variety
of pharmacological properties. And 6 of these saponins
are the same to those of ginsenosides, such as Gyp-3, 4, 8,
12 are Gin-Rb1, Rb3, Rd, F2 [4]. But the medicinal proper-
ties of GPs have been mainly attributed to the saponins. A
general structure of dammarane-type gypenoside is illus-
trated in Figure 1.
Recently, interests in understanding the cardiovascular
property of GPs appear to be mounting. And the anti-
hyperlipidemic effect has been observed in human and
animal studies, with an efficacy that is comparable to
most of the current natural products [5,6], suggesting its
safety and effective through chronic clinical treatment of
hyperlipidemia. However, the mechanism underlying thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 General structure of dammarane-type gypenosides. R1/R2=glucose, rhamnose; R3=glucose, xylose.
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conduct an experiment to investigate the cholesterol-
lowering effects of GPs in the high-fat and high-
cholesterol induced hyperlipidemic rats.
Methods
Materials and agents
Simvastatin (Merk Sharp & Dohme Limited U.K.) was
used as a positive control cholesterol-lowering drug.
Gypenosides tables were purchased from Hutchison
Whampoa Guangzhou Baiyunshan Chinese Medicine
Company Limited (Z10900032).
The HFHC rodent chow, containing cholesterol 3%,
cholic acid 0.2%, propylthiouracilum 0.5% and lard 10%,
was supplied by Guangdong Medicinal Laboratory Animal
Center, Guangzhou, China, Certification, SCXK 2008–0002.
Animal model and treatment
Forty eight adult male healthy Wistar rats (supplied by
Guangdong Medicinal Laboratory Animal Center,
Guangzhou, China, Certification, GDMLAC 2007A056),
weighing 180–200 g, were kept in wire-bottomed cages
under a 12 h light/dark cycle and controlled temperature
(25 ± 1°C) and relative humidity of 40–60%, and had
free access to standard lab chow and tap water. All
experimental protocols have got clearance from Institu-
tional Animal Ethics Committee of Guangdong Pharma-
ceutical University (GDPUIAEC No. 200902), which is in
a compliance with national and international guidelines
of animal welfare (NIHGuide for the Care and Use of
Laboratory Animals, NIH publication No. 85–23, 1985).
After 1 week of accommodation, all of the animals
were then divided into 2 groups by weight randomly;
group 1, 8 rats were fed with normal diet (ND) until
sacrifice, serving as normal-diet controls, while group 2,
the other 40 rats were fed with a HFHC diet for continu-
ous 4 weeks to induce hyperlipidemia animal model.
Then the rats that fed the HFHC diet after 4 weeks were
randomly divided into 5 groups (n=8, respectively)depend on TC levels. GPs table (200 mg/kg, 100 mg/kg
and 50 mg/kg) or simvastatin (10 mg/kg) or vehicle in
saline was orally administered at the described below
dosage respectively, concomitantly continued HFHC diet
for 15g/rat/d. The vehicle rats were orally dosed with
the same volume of saline, following the HFHC diet for
15g/rat/d. The same subsequent treatments last for con-
tinuous 5 weeks. The control rats were administrated
with saline and normal lab standard rodent chow instead
of HFHC diet and GPs tables for the whole experimental
period. During the experiment, animals were weighed
weekly, and 24 h food consumption was recorded with
the day of treatment with GPs tables or control as day 0.
Blood sampling
Blood samples were taken (following fasting for 12
hours) before, after, and at the indicated days during the
treatment from the eye socket vein of the rats at room
temperature for coagulation. Serum samples were ob-
tained by centrifugation at 4000 r/min, 4°C for 10 min.
Serum LDL-C, TC, TG, HDL-C, GSH-Px, SOD, CAT
and MDA levels were assayed by Automatic Biochemical
Analyzer (Aeroset 09D0501, American).
Liver sampling
Animals were sacrificed by decapitation and peritoneal cav-
ity was flushed immediately with 10 ml of cold saline.
Livers were excised and 0.2 g liver of each rat was homoge-
nized in 2 ml precooled chloroform-methanol (1:1) at 4°C
to gain a final concentration of 10%. The supernatant was
then centrifuged at 4000 r/min, 4°C for 10 min and stored
at −70°C for future analysis. The left lobe of liver was cut
into 1 cm × 1 cm × 0.5 cm, fixed in 10% formaldehyde,
then embedded in paraffin, sectioned, and stained with HE
to analysis the histological change by optical microscope.
Bioassays
Levels of TC, TG, HDL-C and LDL-C, GSH-Px, SOD,
CAT and MDA in serum were determined by Automatic
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the rat liver preparation was determined by Automatic
Biochemical Analyzer.
HMG-CoA Reductase assay
The liver cell pellet was homogenized at 4°C in a Dounce
homogenizer in 20 mM PBS (pH 7.4), 1 mM EDTA, and
30 mM nicotinamide. The HMG-CoA reductase assay
was performed according to a previous report [7]. The
enzyme reaction was linear with time up to 60 min and
for protein concentrations up to 0.5 mg. Protein content
was measured by the Bradfod method [8].
Statistical analysis
All results were expressed as mean ± SEM. The data
were evaluated by one-way ANOVA, and the differences
between the means were assessed using Duncan’s test.
P< 0.05 was considered as statistically significant.
Results
Anti-hyperlipidemic effects of GPs
As showed in Figure 2, serum TC, TG and LDL-C levels
were markedly elevated (from 1.83±0.03 mmol/ml to
4.19±0.11 mmol/ml for TC, 0.74±0.04 mmol/ml to 1.70
±0.12 mmol/ml for TG and 0.28±0.01 mmol/ml to 0.70
±0.12 mmol/ml for LDL-C), while serum HDL-C levels
were significantly decreased (from 1.14±0.03 mmol/ml
to 0.67±0.12 mmol/ml) after they were fed with HFHC
diet for 4 weeks. And there were statistically significant
between the experimentally induced hypercholesteole-
mic groups and the control group (P<0.05). Administra-
tion of GPs table led to significant reduction of serum
TC, TG and LDL-C, as compared to those in the
hypercholesteolemic model group. In addition, the re-
duced levels of HDL-C in the HFHC-fed rats were dose-Figure 2 Changes of lipids before and after HFHC-diet for 4 weeks.dependently reversed by GPs with a dosage range from
50 to 200 mg/kg.
In particular, compared with simvastatin (10 mg/kg),
GPs tables (200 mg/kg) exhibited a similar effect of the
improvement on serum lipid profiles in the hyperlipid-
emic rats (Figure 3).
Effects of GPs on serum GSH-Px, SOD,
CAT and MDA levels
Oxidative stress has been regarded as a common patho-
genic mechanism in various liver diseases. In Figure 4,
the antioxidant activities of GPs were determined by
measuring the serum GSH-Px, SOD, CAT and MDA
levels. The MDA levels increased in the HFHC model
group but decreased levels of SOD and GSH-Px activity
compared with those observed in the control group, sug-
gesting that HFHC diet may lead to the imbalance be-
tween oxidative stress generation and antioxidant
formation. However, GPs treatment significantly re-
versed those values, indicating that GPs may prevent the
pathological process (Figure 4).
Effects of GPs on TC and TG levels in liver of rats
As showed in Figure 5, TC and TG levels in liver of
HFHC-induced rats were markedly elevated compared
with those in the control groups (P<0.05). Administration
of GPs table led to significant reduction of liver TC and
TG, as compared to those in the hypercholesteolemic
model group. In addition, the reduced levels of TC in the
HFHC-fed rats were dose-dependently reversed by GPs
with a dosage range from 50 to 200 mg/kg.
Importantly, GPs tables (200 mg/kg) showed a similar
effect of the down-regulation on liver lipid profiles in the
hyperlipidemic rats compared with simvastatin (10 mg/kg),
indicating the potential of protecting liver by GPs.
Figure 3 The hypolipdeamic effect of GPs on HFHC-induced hyperlipidemic rats.
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effects of gypenosides on HMG-CoA reductase activity
were analyzed here. The result showed that GPs can
inhibit the activity of HMG-CoA by 20 to 50% in a
dosage-dependent way (Table 1).
Discussion
Dyslipidemia is a metabolic disorder that attributes to
atherosclerosis and cardiovascular disease. It is usually
elevated serum levels of TC, TG and LDL-C, accom-
panied by reduced HDL-C levels. According to ATP
repots, LDL-C was identified as a powerful atherogenic
lipoprotein and was identified as the primary target of
cholesterol-lowering therapy. However, HDL-C carries
cholesterol and cholesterol esters from the peripheral
tissues and cells to the liver, where cholesterol isFigure 4 Effects of GPs on hepatic function of HFHC induced hyperlipmetabolized into bile acids [9]. It means that increasing
HDL-C levels will lower CHD morbidity and mortality.
What’s more, dyslipidemia will generate redundant free
radicals, such as O2-, H2O2 and ·OH for metabolic dis-
order. And MDA, a marker of lipid peroxidation and
oxidative stress, damages cells and tissues [10].
The current theory of the oxidative modification hy-
pothesis states that LDL becomes oxidized in the arterial
wall where it then lends itself to cellular uptake and
foam cell formation. It’s said that SOD, CAT and GSH-
Px are the three key antioxidant enzymes in the body,
which help free radicals to react with other chemicals to
produce safe, instead of toxic substances [11].
SOD is responsible for neutralizing the most common
free radical, which is known as superoxide. It also aids
the body’s utilization of copper, zinc and manganese.idemic rats (x±s, n=8 for each group).
Figure 5 Effects of GPs on TC and TG content in liver of high lipid diet induced hyperlipidemic rats (x±s, n=8 for each group).
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damage by converting the highly reactive radicalsuperox-
ide (O2-) into the less reactive peroxide (H2O2), which can
be destroyed by CAT to form water and molecular oxygen.
In turn, glutathione-bound enzymes, particularly GSH-Px,
the most abundant intracellular nonproteinthiol, have pro-
minent antioxidant and detoxification properties, since
they can accept electrons from electron donors, like re-
duced glutathione, and, thus, form conjugates with some
harmful compounds for detoxification. GSH-Px, along
with SOD, is one of the body’s endogenous antioxidants
and is well known to protect liver cells against oxidative
damage through chemical or enzymatic reactions [12-14].
Recently, lots of studies are conducted to investigate
the anti-hyperlipidemic mechanism in different models.
In the hyperlipidemia rat model induced by P407, gynos-
temma activity was examined, and it showed to be ef-
fective in significantly lowering TG and TC levels, and
showed a trend in lowering LDL cholesterol levels in
chronic studies. Importantly, they found an improve-
ment of plasma nitrite levels in this model, indicating
the potentiality of treating and/or preventing cardio-
vascular diseases [15]. Furthermore, they also examined
the pharmacological anti-hyperlipidemic effectiveness ofTable 1 Effects of gypenosides on HMG-CoA
reductase activity
HMG-CoA reductase activity,
pmol mevalonate formed/ mg
protein per min
Blank group 50.1 ± 3.2
GPs group 50 mg/Kg 40.7 ± 2.8
100 mg/Kg 32.4 ± 2.2
200 mg/Kg 24.3 ± 1.9Gynostemma pentaphyllum in the obese Zucker fatty
diabetic rat model. After treatment for 4 days Gynos-
temma pentaphyllum 250 mg/kg reduced triglyceride
(33%), total cholesterol, (13%) and low density lipopro-
tein cholesterol levels (33%). These effects were dose-
dependent and maintained for at least 5 weeks [16,17].
In the study, we investigated the levels of GSH-Px, SOD,
CAT, MDA, TC, TG, HDL-C and LDL-C in the serum be-
fore/after the treatment and TC, TG in the liver after the
treatment. After the treatment for 5 weeks, the levels of
TC, TG and LDL-C dose-dependently decreased signifi-
cantly in the treatment groups compared with the control
group. While the HDL-C content was up-regulated in the
treatment groups compared with the control group, espe-
cially in the dose of 200 mg/kg, which showed a similar ef-
fect of the down-regulation on lipid profiles both in the
serum and liver in the hyperlipidemic rats compared with
simvastatin (10 mg/kg). In addition, compared to the con-
trol group, levels of GSH-Px decreased by 13.78%, SOD by
38.41%, CAT by 13.57% while MDA increased by 35.99%
in the HFHC-induced group. By contrast, in the simva-
statin (10 mg/kg) group, GSH-Px increased by 25.40%,
CAT by 12.5%, MDA by 6, but SOD decreased by 35.5%.
However, in the dose of 200 mg/kg, levels of GSH-Px in-
creased by 45.57%, CAT by 68.19%, but SOD decreased by
1.18%, MDA by 8.6%. Moreover, in this study, we also ob-
served the marked pathological differences among the six
groups. The HFHC-induced hyperlipidemic group showed
some pathological abnormalities in liver compared to the
control group, which showed normal morphology. The
effect of GPs on tissue pathology demonstrated some posi-
tive protective findings. We can find some moderate
changes in the GPs treatment group compared to the se-
vere changes in the HFHC-induced hyperlipidemic group,
investigating the hepatic-protective potential of GPs.
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The results suggest that GPs can effectively regulate the
lipid metabolism in the HFHC-induced hyperlipidemic
rats and show a hepatic-protective activity. Further re-
search should pay more attention to the hypolipidemic
mechanism of GPs.
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